Overview

Aureka Biotechnologies is an AI-native TechBio company with bases in Laguna Hills, California and Shanghai. It develops biological foundation models (AuraIDE; open-source OpenDDE) and Lab-in-the-Loop infrastructure that couples molecular generation with high-throughput experimental validation for antibody discovery. Founded in 2023 by Dr. Weian Zhao. In August 2026 Aureka raised a $100 million Series B with Granite Asia funding the first tranche exclusively, a strategic investor leading a subsequent tranche, and participation from HighLight Capital, MPCi, and NRL Capital — nearly $200 million raised to date. The company cites strategic pharma partnerships and tens of millions in revenue over two years.

Why Aureka Biotechnologies is interesting

$100M Series B (Aug 2026, ~$200M cumulative) to scale AuraIDE — models that improve from proprietary Lab-in-the-Loop experiments, not only public protein datasets.

Product & use cases

Closed-loop AI-for-science stack: biological foundation models plus single-cell functional screening and automated experiments that feed continuous model post-training for antibody design.

• De novo antibody and biomolecular design with wet-lab feedback
• Partner with pharma on hard targets (e.g., GPCRs, dual-target antibodies)
• Benchmark and extend open biomolecular models via OpenDDE

Key facts

• Series B (Aug 2026): $100M; ~$200M cumulative (PR Newswire)
• First tranche: Granite Asia (exclusive); later tranche led by undisclosed strategic; HLC, MPCi, NRL follow-on
• Products: AuraIDE foundation model; OpenDDE open-source; Lab-in-the-Loop platforms
• Tens of millions revenue over ~2 years from discovery partnerships (company)
• No VCT /fund/ IDs yet for Granite Asia / HLC / MPCi / NRL — names press-sourced

Fundraising history

Competitive landscape

Edge: Owns the experimental flywheel that generates proprietary functional data for foundation-model training — not only static public corpora.

Buyers increasingly want closed-loop platforms that produce developable assets, not structure scores alone. Aureka’s underwriting questions are partner concentration, geography/IP, and how fast Lab-in-the-Loop data improves real programs.

• Chai Discovery adjacent

  Structure/design-focused TechBio peer in the foundation-model wave.

• Classic CRO + ML bolt-ons adjacent

  Experiment capacity without owned biological foundation models.

• Pharma internal AI groups adjacent

  Build-vs-buy partners and competitors depending on program.

Industries

Related funding articles

Venture Capital Tracker pieces that cover Aureka Biotechnologies's financing or category context.

• Aureka’s $100M Series B: Lab-in-the-Loop Biological Foundation Models
• August 10–11 VC News Roundup: Counter-Drone, Defensive Cyber AI, Optics & Live Commerce